The rapid advancement of artificial intelligence (AI) has made significant strides in many sectors, and the realm of healthcare is no exception. Among the promising innovations is the use of AI-powered digital twins in clinical trials, particularly those targeting complex diseases like Amyotrophic
African swine fever (ASF) is a highly contagious and deadly viral disease affecting both domesticated and wild pigs. With its widespread prevalence in areas such as Africa, Europe, Asia, and the Caribbean, this disease has significant economic implications. Recent estimates state that if ASF were
Clinical trials have long been a cornerstone of medical research, essential for the development and approval of new drugs and treatments. However, they are often plagued by high costs, time constraints, and the complexities associated with patient recruitment. In recent years, the transformative
The article delves into the intriguing potential of real-world evidence (RWE) to revolutionize the U.S. Food and Drug Administration’s (FDA) approval process for new drugs. By relying more on real-world data (RWD), regulatory decisions could become quicker, more economical, and maintain the current
Roche has recently entered into a groundbreaking multi-year collaboration with Oxford BioTherapeutics (OBT), valued at over a billion dollars, to spearhead the development of novel antibody-based cancer treatments. This significant partnership focuses on the creation of innovative therapies such as
Schrödinger, a well-established player in the computational chemistry and drug discovery space, has recently made headlines by embracing artificial intelligence (AI). The company’s CEO, Ramy Farid, officially announced this strategic pivot during the presentation of the company's year-end re
